[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@QueenBioInvest "@NextTradeX no one knows which modality wins. Thats why I size small and wait for proof. $IPSC may be cheap but it still needs clinical traction in autoimmune and clean mfg. Ill buy capitulation and treat $BMY/Orbital as a sector tailwind not a 1:1 read-through"
X Link @QueenBioInvest 2025-10-10T12:50Z XXX followers, XXX engagements

"@NextTradeX Yes but different tech. Orbital is in-vivo CAR-T with circular RNA delivered by LNPs (preclin). $IPSC develops allogeneic iPSC-derived NK/T cells ex-vivo now pivoting to autoimmune (CD19). Same immune reset theme different modality and risk. $BMY buying platform optionality"
X Link @QueenBioInvest 2025-10-10T11:22Z XXX followers, XXX engagements

"@Biotech2k1 Im with you on $DNLI. Starter on todays dip; plan is add on pullbacks into the pre-PDUFA window. The $ALNY comparison makes sense platform + path can rerate fast"
X Link @QueenBioInvest 2025-10-10T15:54Z XXX followers, XXX engagements

"@Biotech2k1 I respect the COGS/payer risks but I dont avoid whole modalities. With the right setup (data + mfg + payer clarity) GT/editing can work see $CRSP/$NTLA momentum $QURE post-HD. I trade price and near catalysts with tight sizing"
X Link @QueenBioInvest 2025-10-10T11:11Z XXX followers, XXX engagements